Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/19/2026, 12:00:00 AM
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
Korean Translation
특정 신세포암(RCC) 환자의 보조 치료를 위한 웰리렉과 키트루다 병용 요법에 대한 FDA PDUFA 목표일이 2026년 6월 19일로 예정됨.
Related Recent Events
Life Time Group Holdings Inc (LTH) · Earnings Release
Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.
8/4/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.
7/21/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
6/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.
6/12/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Novo Nordisk to host an R&D investor event to discuss data from the ADA 2026 Scientific Sessions, including Phase 3 results for CagriSema on 2026-06-07; High importance is estimated as Phase 3 data for key pipeline assets typically drives >10% price movement, scheduled.
6/7/2026, 12:00:00 AM